Brewin Dolphin Wealth Management’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-150
Closed -$4K 376
2021
Q4
$4K Hold
150
﹤0.01% 303
2021
Q3
$6.16K Hold
150
﹤0.01% 305
2021
Q2
$8.5K Hold
150
﹤0.01% 301
2021
Q1
$6.3K Sell
150
-130
-46% -$7.41K ﹤0.01% 294
2020
Q4
$19.6K Hold
280
﹤0.01% 228
2020
Q3
$7.86K Buy
+280
New +$9.12K ﹤0.01% 242

Other funds holding EDIT

Brewin Dolphin Wealth Management's EDIT Position: Q1 2022 in Review

Brewin Dolphin Wealth Management sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 150 shares — an estimated $4K sold.

Brewin Dolphin Wealth Management first reported a position in EDIT in Q3 2020 and held it in 6 quarters. The position peaked at $19.6K in Q4 2020. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

  • Brewin Dolphin Wealth Management reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
  • Brewin Dolphin Wealth Management sold 150 Editas Medicine shares in Q1 2022, an estimated $4K.
  • Brewin Dolphin Wealth Management first reported a position in Editas Medicine in Q3 2020 and held it in 6 quarters.
  • Brewin Dolphin Wealth Management's Editas Medicine position peaked at $19.6K in Q4 2020.
  • 256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q1 2022, filed 14 Nov 2022.